Instituto Português de Oncologia do Porto

What Instituto Português de Oncologia do Porto does

Instituto Português de Oncologia do Porto (IPO Porto) is a Portuguese public healthcare institution (E.P.E. – Entidade Pública Empresarial) operating under the Ministry of Health and the Serviço Nacional de Saúde (SNS) as a comprehensive cancer center serving Northern Portugal. Founded in 1974, it is one of three national oncology institutes (alongside IPO Lisboa and IPO Coimbra) and holds OECI Comprehensive Cancer Centre accreditation (2022–2027), ESMO Integrated Oncology and Palliative Care reaccreditation, JACIE bone marrow transplantation accreditation, CHKS hospital accreditation (2023–2025), and IASIOS interventional radiology accreditation. The institution provides end-to-end oncology services including diagnostic imaging (MRI, CT, PET-CT, SPECT/CT), radiotherapy (Novalis-certified), nuclear medicine, surgical oncology, medical oncology, bone marrow transplantation, cellular therapy including CAR-T cell production, precision oncology, and psycho-oncology support. It also operates a digital patient services platform (Bem-me-ker kiosks and mobile app), a regional cancer registry (RORENO), an oncology research center (CI-IPOP, rated Excellent by FCT), and an oncology nursing school (EPOP).

The technology stack is anchored in a modernized clinical infrastructure funded by approximately €38 million from Portugal's Plano de Recuperação e Resiliência (PRR, 2024–2026), supporting robotic-assisted surgery, advanced imaging renewal, in-house CAR-T cell manufacturing, and facility upgrades. AI/ML capabilities are embedded across multiple EU-funded research programs (AIDA, HENKO, PAINLESS, ONCOVALUE, PRIME-ROSE) covering computer vision for endoscopy, predictive analytics for palliative care needs, generative AI for personalized therapeutic strategies, and anomaly detection in cancer progression. Patient access is via the NHS referral pathway, telemedicine, and an unscheduled care service (SANP), with revenue derived from public healthcare budgets rather than commercial pricing. The institution has active leadership positions in numerous European consortia (over 50 partners across 23 countries in Hope4Kids alone) and is preparing its Porto Comprehensive Cancer Center (PCCC) to integrate into Cancer Core Europe.

Name

Instituto Português de Oncologia do Porto

Legal name

Instituto Português de Oncologia do Porto Francisco Gentil, E. P. E.

Website

https://ipoporto.pt

Company type

Private

Founded year

1974

Operating status

Operating

Headcount range

1,001–5,000 employees

Short description

Portuguese public comprehensive cancer center in Porto, providing oncology diagnosis, treatment, research, and education for Northern Portugal under the National Health Service, with OECI accreditation and extensive European research collaboration.

Ownership category

akta.pro rank

Product category

Oncology Hospital Services

NAICS

Specialty (except Psychiatric and Substance Abuse) Hospitals (62231)

SIC

Services-Hospitals (8060)

akta.pro primary industry

Oncology & Cancer Specialty Hospitals (HLAFAHAC)

akta.pro secondary industries

Medical Oncology (HLAKAFAB), Hospital-Integrated Cancer Centers (Acute Oncology Programs) (HLAFAAAM), Surgical Oncology (HLAKAFAG), Breast Oncology (HLAKAFAJ)

Keywords

• Oncology hospital services
• Cancer treatment center
• Radiation therapy services
• Cellular therapy programs
• Clinical oncology research

Headquarters

HQ city

Porto

HQ country

Portugal

HQ region

Europe

Offices1 record

Markets served

GTM type

B2C

Offering type

Services

Cost components

Personnel, Operations, Technology or R&D, Infrastructure, Supply Chain

Distribution channels4 records

Marketing channels8 records

Core offering

Instituto Português de Oncologia do Porto (IPO Porto) is a comprehensive public cancer center providing oncology diagnosis, treatment, and follow-up care for Northern Portugal. Its offerings span specialized medical departments (nuclear medicine, radiotherapy, bone marrow transplantation, cellular therapy including CAR-T, psycho-oncology, breast clinic), precision oncology, clinical trials, a digital patient platform (Bem-me-ker), the regional cancer registry (RORENO), research (CI-IPOP), and oncology education (EPOP).

Product overview

Instituto Português de Oncologia do Porto (IPO Porto) is a comprehensive cancer center providing oncology services through multiple specialized medical departments and clinics. The institution offers a digital patient services platform called Bem-me-ker (electronic kiosks and mobile app), advanced radiotherapy, nuclear medicine, bone marrow transplantation, and cellular therapy services including CAR-T cell production. The research arm includes a comprehensive cancer center (P-CCC), investigation center with multiple research groups, a regional cancer registry (RORENO), and educational institution (EPOP). Major infrastructure investments through PRR funding support robotic surgery, technological modernization, and facility renovations.

Differentiator

Problem solved

Functional benefit

Brands

• Bem-me-Ker: Electronic kiosk system and mobile application for patient appointment management and check-in
• RORENO
• EPOP - Escola Portuguesa de Oncologia do Porto
• Porto Comprehensive Cancer Center

Products and services

• Serviço de Medicina Nuclear (Nuclear Medicine Department)

Quantifiable outcome

• Awarded 4 categories in SNS Awards 2023 demonstrating excellence in healthcare delivery
• +3 more outcomes

Segments4 records

Ideal customer profiles4 records

Technology focussed No

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

AI capability7 records

Feature6 records

Partnerships

22 partnerships are on record, tiered core and minor.

• UTAD - Universidade de Trás-os-Montes e Alto DourocoreStrategic or Co-development PartnerPartnership for the 'Tu és o tipo de alguém' blood donation campaign targeting young donors aged 18-40. Joint initiative to combat myths and misinformation about blood donation.
• Fundação "la Caixa"coreStrategic or Co-development PartnerProtocol agreement establishing the Espaço Fundación "la Caixa" at IPO Porto for psychosocial support services. Partnership includes funding for the Equipa de Apoio Psicossocial (EAPS) team providing psychological and social support to patients and families.
• RISE - Research Unit for Interfaces, Structures and SurfacescoreStrategic or Co-development PartnerIPO Porto is a founding member of RISE, an associated laboratory approved by FCT for multidisciplinary research.
• OECI - Organization of European Cancer InstitutescoreStrategic or Co-development PartnerIPO Porto holds OECI accreditation as a Comprehensive Cancer Centre and the President of IPO Porto was elected to OECI's Board, indicating active leadership in the European cancer centre network.
• Princess Máxima Center for Pediatric Oncology (Netherlands)coreStrategic or Co-development PartnerCoordinator of the Hope4Kids Joint Action project, the largest European initiative on pediatric palliative care, involving over 50 partners from 23 countries.
• Hope4Kids Consortium - 23 European CountriescoreStrategic or Co-development PartnerEU Joint Action 'Holistic Oncological Palliative Care 4 Europe's Kids' aiming to strengthen and harmonize pediatric palliative care across Europe with 50+ partners.
• eCAN Plus Consortium - 23 European CountriescoreStrategic or Co-development PartnerEU flagship project in digital oncology and cross-border health data exchange involving 81 organizations from 23 European countries, testing safe integration of digital tools and health data.
• ONCOSCREEN ConsortiumcoreStrategic or Co-development PartnerEU Horizon project (€12.97M) for colorectal cancer screening using novel risk-based methods involving 38 partners.
• PCM4EU Consortium - 15 European CountriescoreStrategic or Co-development PartnerEU4Health project (€3.68M) improving access to personalized cancer medicine across Europe, IPO Porto serves as WP Leader.
• PRIME-ROSE ConsortiumcoreStrategic or Co-development PartnerEU Horizon project (€5.97M) developing DRUP-like clinical trials for precision cancer medicine repurposing across Europe.
• TOGAS ConsortiumcoreStrategic or Co-development PartnerEU4Health project (€11.34M) for gastric cancer screening implementation in European countries with IPO Porto as WP Leader.
• AIDA Project ConsortiumcoreStrategic or Co-development PartnerEU Horizon project (€6.33M) developing AI diagnostic assistant for gastric inflammation and cancer prevention, IPO Porto serves as PI and WP Leader.
• CCI4EU - Comprehensive Cancer InfrastructurescoreStrategic or Co-development PartnerEU Horizon project strengthening research capacities of Comprehensive Cancer Infrastructures across Europe.
• PAINLESS ConsortiumcoreStrategic or Co-development PartnerEU Horizon project (€5.95M) developing home-based neuromodulation for pain relief in palliative cancer care.
• ONCOVALUE ConsortiumcoreStrategic or Co-development PartnerEU project implementing AI-based framework for assessing real-world effectiveness of cancer therapies across European hospitals.
• MINDFULNESS / MindGaP ConsortiumcoreStrategic or Co-development PartnerEU FET Open project exploring exosome biomarkers and mindfulness effects on cancer, with European university partners.
• PROSTAMET ConsortiumcoreStrategic or Co-development PartnerEU Marie Skłodowska-Curie Doctoral Network on lipid metabolism in prostate cancer with KU Leuven as coordinator.
• Porto Comprehensive Cancer Center (PCCC)coreStrategic or Co-development PartnerPartnership integrating multiple cancer research entities preparing to join Cancer Core Europe network of leading European cancer centers.
• IEFP - Instituto do Emprego e Formação ProfissionalminorOthersAwarded the 'Selo Marca Entidade Empregadora Inclusiva' (Inclusive Employer Mark) by IEFP for commitment to inclusive employment practices.
• SPMS - Serviços Partilhados do Ministério da SaúdecoreTechnology or IntegrationProtocol for health information systems integration with SNS shared services.
• HENKO NET ConsortiumcoreStrategic or Co-development PartnerInterreg SUDOE project (€158K) developing AI platform for early palliative care detection in Portugal, Spain, and France.
• Cancer Core EuropecoreStrategic or Co-development PartnerNetwork of leading European cancer centers that PCCC is preparing to integrate.

Scale indicators7 records

Recent moves10 records

Expansion highlights7 records

Regional players

• Centro Hospitalar Universitário de São João: Major Portuguese university hospital in Porto providing overlapping oncology and surgical services within the Northern region. Comparable as a public NHS teaching hospital competing for the same patient catchment.
• Champalimaud Foundation — Champalimaud Clinical Centre: Lisbon-based private philanthropic cancer and neurosciences center. Comparable as an Iberian comprehensive cancer center with strong research emphasis, partly competing for Portuguese oncology talent and trial activity.

Broad incumbents

• Netherlands Cancer Institute (NKI): Dutch comprehensive cancer center combining hospital and research institute functions. Comparable as a publicly anchored, OECI-style cancer center with strong basic/translational science program.
• Institut Gustave Roussy: Europe's largest comprehensive cancer center in Villejuif, France. Comparable as a publicly funded, research-led oncology institution with strong EU clinical-trial activity and OECI accreditation.
• Karolinska Comprehensive Cancer Centre: Swedish university hospital cancer center providing multidisciplinary oncology care, research, and training within a public-health system — directly comparable in mission and European leadership profile.
• The Christie NHS Foundation Trust: Largest single-site cancer hospital in Europe, operating within the UK NHS. Comparable as a publicly funded, research-active, tertiary cancer center with comprehensive service line-up including CAR-T and radiotherapy.
• Vall d'Hebron Institute of Oncology (VHIO): Leading Spanish comprehensive cancer center affiliated with Vall d'Hebron University Hospital. Directly comparable as a publicly anchored, research-intensive European cancer center operating across clinical care, trials, and translational science.

Emerging players

• Princess Máxima Center for Pediatric Oncology: Dutch national pediatric oncology center, the lead partner of IPO Porto on the Hope4Kids EU Joint Action. Comparable as a specialized oncology center and EU pediatric palliative care research hub.

Direct peers

• Instituto Português de Oncologia de Coimbra Francisco Gentil (IPO Coimbra): Third Portuguese Oncology Institute, covering the Central region. Same E.P.E. public enterprise model, comparable comprehensive oncology service portfolio and accreditation standing.
• Instituto Português de Oncologia de Lisboa Francisco Gentil (IPO Lisboa): Sister Portuguese Oncology Institute serving the Lisbon/Tagus Valley region with the same comprehensive cancer center mandate (prevention, treatment, research, teaching). Directly comparable as the other pillar of the Grupo Hospitalar IPO.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat6 records

Key risks7 records

Key highlights7 records

Customer concentration

• Facebookfacebook.com/ipodoporto
• LinkedInlinkedin.com/company/ipoporto

Revenue estimate

Valuation estimate

Number of profiles

Profiles2 records

Subsidiaries4 records

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Instituto Português de Oncologia do Porto